{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:05Z","timestamp":1793075585800,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008235","name":"University of Utah School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jlb.2026.100495","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:29:24Z","timestamp":1790576964000},"page":"100495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Web-based application of integrated clinico-genomic prognostic nomograms in metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Muhammad Zaki","family":"Fadlullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aik Choon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-6614","authenticated-orcid":false,"given":"Manish","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jlb.2026.100495_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11523-025-01148-2","article-title":"A bayesian network meta-analysis of systemic treatments for metastatic castration-resistant prostate cancer in First- and subsequent lines","volume":"20","author":"Wosny","year":"2025","journal-title":"Targeted Oncol"},{"issue":"2","key":"10.1016\/j.jlb.2026.100495_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.euo.2025.07.006","article-title":"Cabazitaxel versus abiraterone or enzalutamide for poor-prognosis metastatic castration-resistant prostate cancer after docetaxel: a phase 2 trial with a circulating tumor DNA analysis","volume":"9","author":"Parekh","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"15","key":"10.1016\/j.jlb.2026.100495_bib3","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.22.02661","article-title":"External validation of a prognostic model of overall survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"41","author":"Halabi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jlb.2026.100495_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.0300","article-title":"Bellmunt risk score as a prognostic tool in metastatic castration-resistant prostate cancer survival","volume":"9","author":"Buttner","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jlb.2026.100495_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-Based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.jlb.2026.100495_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.eururo.2025.07.011","article-title":"Pathogenic genomic alterations in circulating tumor DNA predict overall survival in men with metastatic castrate-resistant prostate cancer","volume":"89","author":"Halabi","year":"2026","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.jlb.2026.100495_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaf025","article-title":"Multi-gene risk score for prediction of clinical outcomes in treatment-naive metastatic castrate-resistant prostate cancer","volume":"9","author":"Fadlullah","year":"2025","journal-title":"JNCI Cancer Spectr"},{"issue":"19","key":"10.1016\/j.jlb.2026.100495_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194714","article-title":"Plasma copy number alteration-based prognostic and predictive multi-gene risk score in metastatic castration-resistant prostate cancer","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jlb.2026.100495_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/annonc\/mdx689","article-title":"A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone","volume":"29","author":"Wang","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jlb.2026.100495_bib10","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1541-7786.MCR-22-0099","article-title":"Molecular profile changes in patients with castrate-resistant prostate cancer Pre- and post-Abiraterone\/Prednisone treatment","volume":"20","author":"Sicotte","year":"2022","journal-title":"Mol Cancer Res"},{"issue":"5","key":"10.1016\/j.jlb.2026.100495_bib11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.jlb.2026.100495_bib12","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jlb.2026.100495_bib13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jlb.2026.100495_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41391-020-0224-4","article-title":"Plasma cell-free DNA-Based predictors of response to abiraterone acetate\/prednisone and prognostic factors in metastatic castration-resistant prostate cancer","volume":"23","author":"Du","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jlb.2026.100495_bib15","article-title":"Multigene copy number alteration risk score biomarker-based enrichment study designs in metastatic castrate-resistant prostate cancer","volume":"8","author":"Jo","year":"2024","journal-title":"JCO Precis Oncol"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295019542600041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295019542600041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:59:34Z","timestamp":1793073574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295019542600041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":15,"alternative-id":["S295019542600041X"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100495","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Web-based application of integrated clinico-genomic prognostic nomograms in metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100495"}}